Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease
  3. NCT05266092

Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease. — AKIM-CKD  

Chronic Kidney Disease Requiring Chronic Dialysis Clinical Trial

Official title:
Activation of the Contact System and the Immune System in Patients With Chronic Kidney

Clinical Trial Summary

Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05266092
Study type Observational
Source Odense University Hospital
Contact Katrine Pilely, PhD
Phone 0045 20963328
Email kapi@sdu.dk
Status Recruiting
Phase
Start date April 25, 2022
Completion date April 2032
View Details
See also
  Status Clinical Trial Phase
Completed NCT05700851 - Immuno-nutrition Supplementation in Haemodialysis N/A
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Completed NCT01464190 - A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Phase 3
Recruiting NCT06040281 - Smart and Fit for Kidney Transplantation N/A
Active, not recruiting NCT03535922 - Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care N/A
Completed NCT04622709 - Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis Phase 2
Completed NCT04585607 - Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia Phase 4
Completed NCT03182699 - Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Phase 4
Completed NCT03942744 - The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function. N/A
Completed NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia Phase 4
Recruiting NCT04659525 - Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia Phase 4
Completed NCT04125537 - Pathways Project: Kidney Supportive Care
Recruiting NCT03347773 - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity N/A
Recruiting NCT04397653 - Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients Phase 4
Active, not recruiting NCT03938285 - Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal N/A
Completed NCT03525223 - Modulation of Tissue Sodium in Hemodialysis Patients N/A
Completed NCT01324128 - A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Phase 3
Not yet recruiting NCT04600193 - a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06225544 - Lumasiran in Hyperoxalaemic Patients on Haemodialysis Phase 2
Recruiting NCT05209880 - Advance Care Planning in the Emergency Department N/A